<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Fibrinolytic drugs; Enzymes, fibrinolytic; Thrombolytics; Myocardial infarction: management: thrombolytics; Alteplase; rt-PA see Alteplase; TPA see Alteplase; Reteplase; Tenecteplase; Streptokinase; Pulmonary: embolism; Thrombosis: venous; Thromboembolism: pulmonary; Alteplase; Urokinase; Anistreplase" /><meta name="IX" content="Fibrinolytic drugs; Enzymes, fibrinolytic; Thrombolytics; Myocardial infarction: management: thrombolytics; Alteplase; Reteplase; Tenecteplase; Streptokinase; Pulmonary: embolism; Thrombosis: venous; Thromboembolism: pulmonary; Alteplase; Urokinase; Anistreplase" /><meta name="IXN" content="rt-PA see Alteplase; TPA see Alteplase" /><title>2.10.2 Fibrinolytic drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP1569-fibrinolytic-drugs.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP1569-fibrinolytic-drugs.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP1569-fibrinolytic-drugs.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP747-cardiovascular-system.htm">2 Cardiovascular system</a> &gt; <a href="PHP1559-stable-angina-acute-coronary-syndromes-and-fibrinolysis.htm">2.10 Stable angina, acute coronary syndromes, and fibrinolysis</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP1566-management-of-st-segment-elevation-myocardial-infarction-stemi.htm" title="Previous: Management of ST-segment elevation myocardial infarction (STEMI)">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP1576-alteplase.htm" title="Next: ALTEPLASE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>2.10.2 </span>Fibrinolytic drugs</h1><?highlighter on?><div id="pC" class="jN"><p>Fibrinolytic drugs act as thrombolytics by activating plasminogen to form plasmin, which degrades fibrin and so breaks up thrombi.</p> <p>The value of thrombolytic drugs for the treatment of <em>myocardial infarction</em> has been established (<a title=" Management of myocardial infarction" href="PHP1560-management-of-stable-angina-and-acute-coronary-syndromes.htm">section 2.10.1</a>). <strong>Streptokinase</strong> and <strong>alteplase</strong> have been shown to reduce mortality. <strong>Reteplase</strong> and <strong>tenecteplase</strong> are also licensed for acute myocardial infarction. Thrombolytic drugs are indicated for any patient with acute myocardial infarction for whom the benefit is likely to outweigh the risk of treatment. Trials have shown that the benefit is greatest in those with ECG changes that include ST segment elevation (especially in those with anterior infarction) and in patients with bundle branch block. Patients should not be denied thrombolytic treatment on account of age alone because mortality in the elderly is high and the reduction in mortality is the same as in younger patients.</p> <p>Alteplase, reteplase and streptokinase need to be given within 12 hours of symptom onset, ideally within 1 hour; use after 12 hours requires specialist advice. Tenecteplase should be given as early as possible and usually within 6 hours of symptom onset.</p> <p>Alteplase, streptokinase, and <strong>urokinase</strong> can be used for other thromboembolic disorders such as deep-vein thrombosis and pulmonary embolism. Alteplase is also used for acute ischaemic stroke (see <a title="BNF:topic: Ischaemic stroke" href="PHP1526-ischaemic-stroke.htm">section 2.9</a>).</p> <p>Urokinase is also licensed to restore the patency of occluded intravenous catheters and cannulas blocked with fibrin clots.</p> <div id="PHP1570"><h2>Cautions</h2><p>Thrombolytic drugs should be used with caution if there is a risk of bleeding including that from venepuncture or invasive procedures. They should also be used with caution in external chest compression, elderly, hypertension, conditions in which thrombolysis might give rise to embolic complications such as enlarged left atrium with atrial fibrillation (risk of dissolution of clot and subsequent embolisation), and recent or concurrent use of drugs that increase the risk of bleeding.</p> </div> <div id="PHP1571"><h2>Contra-indications</h2><p>Thrombolytic drugs are contra-indicated in recent haemorrhage, trauma, or surgery (including dental extraction), coagulation defects, bleeding diatheses, aortic dissection, aneurysm, coma, history of cerebrovascular disease especially recent events or with any residual disability, recent symptoms of possible peptic ulceration, heavy vaginal bleeding, severe hypertension, active pulmonary disease with cavitation, acute pancreatitis, pericarditis, bacterial endocarditis, and oesophageal varices; also in the case of streptokinase, previous allergic reactions to either streptokinase or anistreplase (no longer available).</p> <p id="PHP1572">Prolonged persistence of antibodies to streptokinase and anistreplase (no longer available) can reduce the effectiveness of subsequent treatment; therefore, streptokinase should not be used again beyond 4 days of first administration of either streptokinase or anistreplase.</p> </div> <div id="PHP1573"><h2>Hepatic impairment</h2><p>Thrombolytic drugs should be avoided in severe hepatic impairment as there is an increased risk of bleeding.</p></div> <div id="PHP1574"><h2>Pregnancy</h2><p>Thrombolytic drugs can possibly lead to premature separation of the placenta in the first 18 weeks of pregnancy. There is also a risk of maternal haemorrhage throughout pregnancy and post-partum, and also a theoretical risk of fetal haemorrhage throughout pregnancy.</p></div> <div id="PHP1575"><h2>Side-effects</h2><p>Side-effects of thrombolytics are mainly nausea and vomiting and bleeding. When thrombolytics are used in myocardial infarction, reperfusion arrhythmias and recurrent ischaemia and angina may occur. Reperfusion may also cause cerebral and pulmonary oedema. Hypotension can also occur and can usually be controlled by elevating the patient's legs, or by reducing the rate of infusion or stopping it temporarily. Back pain, fever, and convulsions have been reported. Bleeding is usually limited to the site of injection, but intracerebral haemorrhage or bleeding from other sites can occur. Serious bleeding calls for discontinuation of the thrombolytic and may require administration of coagulation factors and antifibrinolytic drugs (e.g. tranexamic acid). Rarely further embolism may occur (either due to clots that break away from the original thrombus or to cholesterol crystal emboli). Thrombolytics can cause allergic reactions (including rash, flushing and uveitis) and anaphylaxis has been reported (for details of management see Allergic Emergencies, <a title=" Allergic emergencies" href="PHP1969-allergic-emergencies.htm">section 3.4.3</a>). Guillain-Barré syndrome has been reported rarely after streptokinase treatment.</p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP1576-alteplase"><a href="PHP1576-alteplase.htm" title="ALTEPLASE">ALTEPLASE</a></li><li id="_PHP1580-reteplase"><a href="PHP1580-reteplase.htm" title="RETEPLASE">RETEPLASE</a></li><li id="_PHP1582-streptokinase"><a href="PHP1582-streptokinase.htm" title="STREPTOKINASE">STREPTOKINASE</a></li><li id="_PHP1584-tenecteplase"><a href="PHP1584-tenecteplase.htm" title="TENECTEPLASE">TENECTEPLASE</a></li><li id="_PHP1586-urokinase"><a href="PHP1586-urokinase.htm" title="UROKINASE">UROKINASE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP1566-management-of-st-segment-elevation-myocardial-infarction-stemi.htm">Previous: Management of ST-segment elevation myocardial infarction (STEMI)</a> | <a class="top" href="PHP1569-fibrinolytic-drugs.htm#">Top</a> | <a accesskey="]" href="PHP1576-alteplase.htm">Next: ALTEPLASE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>